Literature DB >> 25052452

Sorafenib in thyroid cancer patients: learning from toxicity.

Olivier Huillard1, Benoit Blanchet2, Pascaline Boudou-Rouquette1, Audrey Thomas-Schoemann3, Johanna Wassermann4, François Goldwasser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25052452      PMCID： PMC4122476          DOI： 10.1634/theoncologist.2014-0156

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Saturable absorption of sorafenib in patients with solid tumors: a population model.

Authors:  Marilyne Hornecker; Benoit Blanchet; Bertrand Billemont; Hind Sassi; Stanislas Ropert; Fabrice Taieb; Olivier Mir; Halim Abbas; Laura Harcouet; Romain Coriat; Alain Dauphin; François Goldwasser; Michel Tod
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

Review 2.  Sorafenib in metastatic thyroid cancer: a systematic review.

Authors:  Ligy Thomas; Stephen Y Lai; Wenli Dong; Lei Feng; Ramona Dadu; Rachel M Regone; Maria E Cabanillas
Journal:  Oncologist       Date:  2014-02-21

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Muscle dysfunction in hyperthyroidism.

Authors:  I D Ramsay
Journal:  Lancet       Date:  1966-10-29       Impact factor: 79.321

5.  Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).

Authors:  Emilie Hénin; Benoit Blanchet; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Gilles Freyer; Michel Vidal; François Goldwasser; Michel Tod
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-20       Impact factor: 3.333

6.  Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

Authors:  Pascaline Boudou-Rouquette; Stanislas Ropert; Olivier Mir; Romain Coriat; Bertrand Billemont; Michel Tod; Laure Cabanes; Nathalie Franck; Benoit Blanchet; François Goldwasser
Journal:  Oncologist       Date:  2012-07-02

7.  Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Authors:  Olivier Mir; Romain Coriat; Benoit Blanchet; Jean-Philippe Durand; Pascaline Boudou-Rouquette; Judith Michels; Stanislas Ropert; Michel Vidal; Stanislas Pol; Stanislas Chaussade; François Goldwasser
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

8.  Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.

Authors:  O Huillard; O Mir; M Peyromaure; C Tlemsani; J Giroux; P Boudou-Rouquette; S Ropert; N Barry Delongchamps; M Zerbib; F Goldwasser
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640
  8 in total
  1 in total

1.  Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.

Authors:  Marco Gallo; Federica Michelon; Anna Castiglione; Francesco Felicetti; Alessandro Adriano Viansone; Alice Nervo; Clizia Zichi; Giovannino Ciccone; Alessandro Piovesan; Emanuela Arvat
Journal:  Endocrine       Date:  2014-11-21       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.